1982 BS (Chemistry, Botany & Zoology) Banares Hindu University
1985 MS (Biochemistry) Banares Hindu University
1988 PhD (Biochemistry) Banares Hindu University
To create an excellent research environment and mentoring to all laboratory members as well as to students who want to gain research experience. Our mission is to prepare our students to achieve their goals and become successful in the field of biomedical sciences.
To unravel the molecular basis of asbestos-induced diseases including mesothelioma and lung cancer and develop therapeutic strategies. My work emphasizes on studying signaling pathways involved in causing these diseases.
2011 - Present Research Associate Professor, Department of Pathology, University of Vermont, Burlington, VT
2001 - 2011 Research Assistant Professor, Department of Pathology, University of Vermont, Burlington, VT.
1997 - 1999 Visiting Scientist, University of Vermont, Vermont, USA
1991 - 1997 Central Drug Research Institute, Lucknow, India
1988 - 1990 USA Post-doctoral Research Associate, University of Michigan, Ann Arbor, Michigan
1985 - 1988 Junior and Senior Research Fellow in the Department of Pediatrics Institute of Medical Sciences, Banares Hindu University, Varanasi, India
1987 Young Scientist Award from Nutrition Society of India
1996 Jyotsnamayee-Raghunath Award from Indian Academy of Neurosciences
1996 Unvas Award from Indian Pharmacological Society
2000 Best poster award in International Conference on Environmental and Occupational Lung Disease, hosted by Industrial Toxicology Research Centre, 29 October-2 November 2000 in Lucknow, India
2004 Best poster award from Vermont Cancer Center
2005 Travel award from GeneSifter
2008 Pilot award from Vermont Cancer Center/Lake Champlain Cancer Research Organization
2010 Invited panel reviewer for Peer Reviewed Medical Research Program (PRMRP)-DOD, FY10 for proposal review for IIRA and Technology/Therapeutic Development (TTD) categories. Mesothelioma Panel.
2011 Editorial Board Member of American Journal of Respiratory Cell and Molecular Biology (an American Thoracic Society Journal)
2011 Shukla A, Barrett TF, MacPherson MB, Hillegass JM, Fukagawa NK, Swain WA, O’Byrne KJ, Testa JR, Pass, HI, Faux SP, and Mossman BT: An ERK2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. Am J Respir Cell Mol Biol 45:906-914, 2011 PMCID: PMC3262687.
2011 Shukla A, Hillegass JM, Macpherson MB, Beuschel SL, Vacek PM, Butnor KJ, Pass HI, Carbone M, Testa JR, Heintz NH, Mossman BT. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. Int J Cancer. 2011 Sep 1;129(5):1075-86. doi: 10.1002/ijc.25763.
2011 Hillegass JM, Blumen SR, Cheng K, MacPherson MB, Alexeeva V, Lathrop SA, Beuschel SL, Steinbacher JL, Butnor KJ, Ramos-Nino ME, Shukla A, James TA, Weiss DJ, Taatjes DJ, Pass HI, Carbone M, Landry CC, and Mossman BT: Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy. Int J Cancer 129:233-244, 2011 PMCID: PMC3017728.
2010 Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Pass HI, Carbone M, Testa JR, Mossman BT. Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer. 2010 Dec 15;9:3142010 Hillegass JM, Shukla A, MacPherson MB, Lathrop SA, Alexeeva V, Perkins TN, van der Vliet A, Vacek PM, Gunter ME, Mossman BT. Mechanisms of oxidative stress and alterations in gene expression by Libby six-mix in human mesothelial cells. Part Fibre Toxicol. 2010 Sep 11;7:26.
2010 Hillegass JM, Shukla A, Lathrop SA, MacPherson MB, Beuschel SL, Butnor KJ, Testa JR, Pass HI, Carbone M, Steele C and Mossman BT: Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann NY Acad Sci 1203:7-14, 2010 PMCID: PMC2936775.
For a complete list of Atri Shukla's publications, please visit PubMed.